Optum Rx Reveals Humira Biosimilar Plan To ‘Support Advancement" Of The Market

 
• By Jessica Merrill

United Health's pharmacy benefit manager outlined plans for early inclusion of up to three biosimilar versions of adalimumab on its formularies in 2023, at parity to the brand.

stone scale
Optum Rx plans to offer Humira brand and biosimilars at parity • Source: Shutterstock

More from Drug Pricing

More from Scrip